ArticleJournal of translational medicine2026
Research on GM1 bound bMSCs loaded with SF hydrogel for spinal cord injury repair.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMonosialotetrahexosylganglioside (GM1), a major ganglioside component, is expressed in the spinal cords of mammals. Gangliosides have been shown to play important roles in various physiological processes, including neuronal protection, neurorepair, and stem cell differentiation. Bone marrow-derived mesenchymal stem cells (bMSCs) were expected to be a good source of cells for clinical transplantation and repair due to their abundance, easy accessibility and lack of ethical restrictions. They can also be induced to differentiate into neurons. However, there is still no ideal delivery material or method that allows the sustained and controlled release of GM1 and bMSCs for clinical use in spinal cord injury (SCI). Silk fibroin (SF)-based hydrogels have emerged as a promising strategy for local, controlled, and sustained drug release in the treatment of various diseases.
methodsIn this study, we developed a SF-based hydrogel for the sustained delivery of GM1 and bMSCs (GM1 + bMSCs@SF hydrogel) and evaluated its therapeutic effect in a rat model of SCI.
resultsThe GM1 + bMSCs@SF hydrogel showed sustained GM1 release in vitro. Treatment with the GM1 + bMSCs@SF hydrogel increased cell cycle exit and neuronal differentiation 1 (Cend1) expression, reduced neuronal pyroptosis and apoptosis, and promoted the differentiation of bMSCs into neurons. Double immunofluorescence staining confirmed a decrease in cell pyroptosis. Moreover, rats treated with the GM1 + bMSCs@SF hydrogel showed significant improvement in motor function recovery, with the Basso, Beattie and Bresnahan (BBB) score at 8 weeks reaching about 71.4% of the normal level, compared with about 30% in the SCI group.
conclusionsThis study will minimize neuronal damage by innovatively using SF hydrogel loaded with GM1 and bMSCs for spinal cord injury repair. It will also explore the molecular mechanisms underlying post-traumatic spinal cord injury repair, opening new therapeutic avenues for spinal cord injury treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.